| Home | Log In | Register | Our Services | My Account | Contact | Help |
Alkane Energy - Back to 100p (ALK)
grevis2 - 25 Jun 2005 13:43
Says Zak Mir of Zaks-TA.com
The stock market is full of hyperbole, especially from tipsters. I chanced upon Alkane Energy today and my immediate reaction was that it is the best stock chart I have ever seen.
This may sound somewhat melodramatic, but I do not think that it is an exaggeration. As all traders know (including Nick Leeson if you are reading), the way to make real money is by betting the bank on the really big calls. That is the aim of my site. Nick, if you're still there, now is the time to go long of Alkane Energy - it has to be a better bet than a Nikkei arbitrage.
Although a chartist is fully allowed to ignore the fundamentals and look purely at the technicals, the fundamental background to Alkane is a company that declared losses of 284,000 pounds in its last set of results versus 20 million pounds in the previous year. This is a great recovery situation just in financial terms and the hopes of the bulls are carried in the form of a very extended base on the chart below 20p that was in place for nearly three years. The charting rule is that the longer the base, the bigger and more powerful the eventual breakout. This would imply that we are looking at the possibility of a full return to the highs seen at the start of the decade towards 100p.
Only an end of day close below the 10 week moving average on the weekly chart at 19p would even begin to cast doubt on the upside. The minimum expected target in the near term would be the 40 week moving average now running through 40p.
js8106455 - 21 Jan 2015 12:08 - 372 of 377
js8106455 - 11 Mar 2015 10:33 - 373 of 377
Bullshare
- 20 Mar 2015 16:36
- 374 of 377
Shares Investor Evenings is going to Manchester, we will showcase four leading companies bringing them together in one room for one evening only.
Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutionsTuesday 31st March 2015
Venue:Lancashire County Cricket Club, Manchester, Emirates Old Trafford, Talbot Road, Manchester, M16 0PX
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Neil O'Brien, CEO - Alkane Energy (ALK:AIM) • Andrew Newland, CEO - Angle (AGL:AIM) • Dr Satu Vainikka, Chief Executive Officer - Valirx (VAL:AIM) • Martin Perrin, Chief Financial Officer - Vipera (VIP:AIM) | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
 | Alkane Energy is one of the UK’s fastest growing independent power generators. The Company operates mid-sized 'gas to power' electricity plants providing both predictable and fast response capacity to the grid. Alkane now has a total of 140MW of installed generating capacity and an electricity grid capacity of 160MW. |
 | ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L). ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. In December 2013, ANGLE secured CE Mark regulatory authorisation for the clinical market in 2013 and FDA approval is planned for 2014. The primary application is the capture of circulating tumour cells (CTCs) in patient blood for: • Early detection of cancer;• Personalised cancer treatment;• Monitoring of cancer patients during treatment; and• Post-treatment monitoring of cancer patients in remission. |
 | Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |
 | Vipera is a leading provider of mobile financial services platforms. The Vipera platform provides the easiest, fastest, most cost-effective way to develop and operate mobile data services. Solutions powered by Vipera run today on more than 500,000 phones, on hundreds of mobile networks in many countries. Founded in 2005, Vipera has offices in Zurich, Milan and London. |
black bird - 16 Sep 2015 10:53 - 375 of 377
a good profit, punters ? I have made very small profit,. BB
LGriffith - 16 Sep 2015 17:18 - 376 of 377
HARRYCAT
- 16 Sep 2015 17:21
- 377 of 377
"ALKANE ENERGY PLC
SUMMARY
· The Boards of Barbican Bidco Limited ("Barbican") and Alkane Energy Plc ("Alkane") are pleased to announce that they have reached agreement on the terms of a recommended cash offer to be made by Barbican (a company controlled by Balfour Beatty Infrastructure Partners, L.P. ("BBIP")) for the entire issued and to be issued share capital of Alkane (the "Offer").
· Under the terms of the Offer Alkane Shareholders will receive:
for each Alkane Share 36p in cash
· The Offer represents a premium of:
(i) 44.00 per cent. to the Closing Price of 25.00 pence per Alkane Share on 15 September 2015 (being the last Business Day prior to this announcement); and
(ii) 59.50 per cent. to the average Closing Price per Alkane Share of approximately 22.57 pence over the six month period ended 15 September 2015 (being the last Business Day prior to the date of this announcement).
· The Offer values the entire issued and to be issued ordinary share capital of Alkane at approximately £61.37 million (assuming the exercise of all outstanding options).
· Barbican is a new company incorporated in England and Wales that has been formed for the purpose of making the Offer.
· The Alkane Directors, who have been so advised by Altium, consider the terms of the Offer to be fair and reasonable. In providing advice to the Alkane Directors, Altium has taken into account the commercial assessment of the Alkane Directors. Altium is providing independent financial advice to the Alkane Directors for the purpose of Rule 3 of the Code.
· Accordingly, the Alkane Directors intend to recommend unanimously that Alkane Shareholders accept the Offer, as they have irrevocably undertaken to do in respect of their entire beneficial holdings.
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Follow us on Twitter